IAVI works closely with a wide array of partners to advance efforts to ensure the development of preventive HIV vaccines. Here you can access important news from our partners.
Thumbi Ndung’u of the University of KwaZulu-Natal on his work towards finding an HIV/AIDS vaccine (The Standard)
IAVI and partners work to identify global health R&D indicators for SDG framework in new report (GHTC)
IAVI was proud to support development of The Guidelines for Conducting Adolescents Sexual and Reproductive Health Research in Kenya under the guidance of the National AIDS and STI Control Programme (NASCOP) and the Kenya Medical Research Institute (KEMRI).
KAVI's Gaudensia Mutua: We need an AIDS vaccine! A clinician's perspective (Vaccines Today)
KAVI's Omu Anzala explains why a vaccine is critical to ending the HIV/AIDS pandemic ()
PEPFAR Ambassador Deborah Birx says HIV disproportionally impacts young women and girls (VOA News)
PEPFAR’s Deborah Birx warns against complacency among researchers in fighting HIV/AIDS (Express Tribune)
Pakistan asks Global Fund for US$11 million to continue its fight against HIV/AIDS and UNAIDS for US$1 million for survey to accurately count infected citizens who are infected (Express Tribune)
UNAIDS highlights recent and anticipated advances in biomedical AIDS research HIV prevention, treatment, and pathogenesis, diagnostics and cure (UNAIDS report)
African health officials announced they will partner with the US to establish African CDC (NPR)
NIH’s Francis Collins and Tony Fauci on the importance of global health research (Science Magazine)
The Bill & Melinda Gates Foundation named Emilio Emini Director of HIV for Global Health (Vaccine News Daily)
NIAID awards Duke researchers grants for HIV vaccine development. (Durham Herald Sun)
South Africa’s Wits Reproductive Health and HIV Institute begin study to determine if sex workers would take daily Truvada pill to prevent HIV infection. (Times SA)
Deborah Birx: "Right things. Right places. Right now” guide PEPFAR programs. (Huffington Post)
Melinda Gates calls for “deliberate efforts” to ensure HIV/AIDS treatment and prevention effectively reach women and girls. (Devex)
UNAIDS says Philippines will spend less by investing heavily in HIV/AIDS prevention. (Philippine Daily Inquirer)
PATH, with NIH and HPTN, launches Phase 2 safety study of long-acting injectable version of rilpivirine as PrEP against HIV. (Release)
NIH awards $16M to Penn-led group to develop synthetic DNA vaccines to fight HIV. (Penn)
Bill Gates calls for innovations to prepare for the next epidemic. (NYTimes)
UNAIDS official says Philippines faces HIV "epidemic." (SunStar)
International Women’s Day & HIV/AIDS: IPM CEO Zeda Rosenberg and U. Pittsburgh professor Sharon Hillier call for new prevention options (Devex). UNAIDS Goodwill Ambassador Victoria Beckham cites inspiration from PEPFAR’s Deborah Birx (Glamour).
Report from Bill & Melinda Gates and Clinton foundations says more needs to be done to reduce HIV infections in adolescent and young women. (Reuters)
UN says Ebola has halted progress in tackling HIV in Sierra Leone. (Reuters)
GSK and Novartis agree complex deal. (AP/Washington Post)
AVAC called for a global action plan to accelerate access to daily oral PrEP and for continued research into new prevention options especially for young African women. (TheBodyPro)
Weill Cornell Medical College said preventing HIV in one person living in the U.S. saves more than $250,000 over their remaining lifetime. (Reuters Health/GlobalPost)
Ragon Institute’s Galit Alter made inspiring call for an HIV vaccine. (BETA)
Merck grants free license for a pediatric HIV medicine to be made and sold inexpensively for use in young children in poor countries hard hit by AIDS. (Washington Post)
US CDC reports more than 700,000 of the 1.1 million people living with HIV in the US are undiagnosed or not receiving care and caused 91.5% of transmissions in 2009. (Washington Post)
HVTN 100, an early-stage vaccine trial aiming to build on RV144 results, launched in South Africa. (NIH)
HPTN 076 and HPTN 077, two prevention trials of long-acting, injectable antiretroviral medications, launched in Africa, Brazil and the US. (NIH)
AVAC’s Mitchell Warren sees lessons for HIV/AIDS advocates in measles vaccine controversy. (The Body Pro)
Balance between a protective antibody response and antigen-specific T-cell activation is critical to vaccine-mediated protection against HIV. (PNAS)
President Obama's proposed $4 trillion budget for fiscal year 2016 would increase funding for CDC's viral hepatitis and HIV prevention efforts but cut overall global health funding. (HIVandHepatitis.com, AVAC)
AVAC lists 10 focus points for HIV prevention advocacy this year. (TheBodyPro)
GSK sets out roadmap for potential 2016 flotation of HIV medicines business. (Reuters)
Gates Foundation CEO: Vaccines Are the Closest Thing We Have to a Miracle. (Daily Beast)
Failure of NIH-funded VOICE trial opens debate about how to run studies. (NYTimes)
National Autonomous University of Mexico (UNAM) specialists are working to develop a vaccine against HIV/AIDS and cancer. (Medical XPress)
Donald Henderson, leader against smallpox, says AIDS remains the world’s main health threat for which there is no vaccine: “The number of people that require drugs is gradually increasing. We’re finding out that it’s not easy to keep these people on drugs indefinitely … And the cost of this is mounting exponentially.” (Voice of America)
Tony Fauci discusses his work fighting HIV and Ebola. (Financial Times)
Adolescent girls most affected by HIV/AIDS globally, reports The Girl Effect; US President announces a PEPFAR, Nike Foundation and BMGF partnership to reduce new infections among adolescent girls in most-affected countries. (The Guardian)
WHO’s executive board endorsed resolution to overhaul capacity to head off and respond to outbreaks (NYTimes). WHO chief Margaret Chan called for integrated approach to address HIV, TB, maternal and child health and public health. (Reuters)
The antibody response in RV144 was made possible by a genetic trait carried over in humans from an ancient ancestry with monkeys and apes, according to a Duke study published in Immunity.
"HIV vaccines should avoid viral target cells, primate model study suggests," according to an Emory Health Sciences paper published in Proceedings of the National Academy of Sciences.
In an op-ed, Professor Tomáš Hanke of the Jenner Institute at the University of Oxford details the difficulties in developing vaccines for HIV and details his research in the area, calling for sustained financial and political support. (Adjacent Government UK)
Abzena announced that its Antitope subsidiary, INSERM and Baylor Institute will collaborate to produce manufacturing cell lines for two novel HIV vaccines.
Los Angeles Times asks: Could 2015 be "the year of the AIDS vaccine?"